[{"address1": "10955 Vista Sorrento Parkway", "address2": "Suite 200", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "858-751-4493", "website": "https://www.januxrx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.", "fullTimeEmployees": 64, "companyOfficers": [{"maxAge": 1, "name": "Dr. David Alan Campbell Ph.D.", "age": 63, "title": "President, CEO & Director", "yearBorn": 1960, "fiscalYear": 2022, "totalPay": 852500, "exercisedValue": 0, "unexercisedValue": 14666733}, {"maxAge": 1, "name": "Mr. Byron  Robinson J.D., Ph.D.", "age": 58, "title": "Chief Strategy Officer", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": 606801, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tighe M. Reardon C.F.A., CPA", "age": 46, "title": "Acting Chief Financial Officer", "yearBorn": 1977, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles M. Winter", "age": 54, "title": "Chief Technical Officer", "yearBorn": 1969, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tommy  Diraimondo Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James  Pennington", "title": "General Counsel", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Brenda  Van Vreeswyk", "title": "Head of Human Resources", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andy Hollman Meyer", "age": 39, "title": "Chief Business Officer", "yearBorn": 1984, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 10, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1714348800, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 56.08, "open": 54.88, "dayLow": 53.78, "dayHigh": 57.11, "regularMarketPreviousClose": 56.08, "regularMarketOpen": 54.88, "regularMarketDayLow": 53.78, "regularMarketDayHigh": 57.11, "beta": 4.177, "forwardPE": -34.7561, "volume": 653416, "regularMarketVolume": 653416, "averageVolume": 1002954, "averageVolume10days": 740600, "averageDailyVolume10Day": 740600, "bid": 56.92, "ask": 57.17, "bidSize": 100, "askSize": 100, "marketCap": 2955489792, "fiftyTwoWeekLow": 5.65, "fiftyTwoWeekHigh": 61.0, "priceToSalesTrailing12Months": 365.64267, "fiftyDayAverage": 40.4553, "twoHundredDayAverage": 17.488874, "currency": "USD", "enterpriseValue": 2624549120, "floatShares": 18606303, "sharesOutstanding": 51660100, "sharesShort": 3443028, "sharesShortPriorMonth": 3110836, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.066599995, "heldPercentInsiders": 0.13776, "heldPercentInstitutions": 0.83275, "shortRatio": 4.49, "shortPercentOfFloat": 0.1423, "impliedSharesOutstanding": 51850700, "bookValue": 7.447, "priceToBook": 7.654089, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -58293000, "trailingEps": -1.32, "forwardEps": -1.64, "pegRatio": -0.24, "enterpriseToRevenue": 324.7, "enterpriseToEbitda": -36.953, "52WeekChange": 2.8, "SandP52WeekChange": 0.23099434, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "JANX", "underlyingSymbol": "JANX", "shortName": "Janux Therapeutics, Inc.", "longName": "Janux Therapeutics, Inc.", "firstTradeDateEpochUtc": 1623418200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "3a638123-d3da-3133-96c7-e6e8cabf84b3", "messageBoardId": "finmb_676965261", "gmtOffSetMilliseconds": -14400000, "currentPrice": 57.0, "targetHighPrice": 100.0, "targetLowPrice": 25.0, "targetMeanPrice": 58.29, "targetMedianPrice": 53.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 344028000, "totalCashPerShare": 6.661, "ebitda": -71024000, "totalDebt": 24542000, "quickRatio": 26.565, "currentRatio": 26.797, "totalRevenue": 8083000, "debtToEquity": 7.127, "revenuePerShare": 0.184, "returnOnAssets": -0.12254, "returnOnEquity": -0.17528999, "freeCashflow": -29519876, "operatingCashflow": -50575000, "revenueGrowth": -0.135, "grossMargins": 0.025980001, "operatingMargins": -6.55709, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-01"}]